Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results suggest that IL-23 and IL-17 may play critical roles in the pathogenesis of AS and IL-23-stimulated production of IL-17 by PBMCs may be responsible for the development of AS.
|
19247658 |
2009 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that overexpression of IL-23, but not IL-17, is a pivotal feature of subclinical gut inflammation in AS.
|
19333939 |
2009 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Besides TNF, the IL-23/IL-17 axis is emerging as an important inflammatory pathway in SpA, as a SNP in the IL-23R locus has been associated with developing AS, mice overexpressing IL-23 develop SpA-like features and IL-17 blockade has been shown to be efficacious for AS patients in a phase II trial.
|
23969080 |
2014 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The reduced serum B7-H3 level was highly negatively correlated with AS Disease Activity Score (ASDAS), TNF-α, and IL-17A.
|
25567370 |
2015 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review provides an overview of the IL-23/IL-17 pathway in the pathogenesis of AS and summarizes new potential treatments for AS and related inflammatory diseases.
|
26080615 |
2016 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERAP1 silencing or inhibition in APCs downregulated HLA-B27 FHC surface expression, reduced IL-2 production by KIR3DL2CD3ε-reporter cells and suppressed the Th17 expansion and IL-17A secretion by AS CD4+ T cells.
|
26130142 |
2016 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CBP30 also inhibited IL-17A secretion by Th17 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.
|
26261308 |
2015 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of the cellular sources and inducers of IL-17 is crucial in our understanding of the drivers of inflammation in AS.
|
27165176 |
2016 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate a genetic role for the IL17/ILRA axis in the development of severe forms of AS.
|
27415816 |
2016 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms of AS in the MEASURE 2 study (NCT01649375).
|
27582421 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin (IL)-23/IL-17 pathway involves in the pathogenesis of ankylosing spondylitis (AS).
|
27846758 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS).
|
27965257 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secukinumab, a fully humanized monoclonal antibody targeting IL-17A, has recently been approved for use in patients with active ankylosing spondylitis.
|
28149838 |
2017 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Searched terms include "anti-TNF" and "Guillain Barré", "IL17 Ankylosing Spondylitis", "Secukinumab" and "TNF-α", "adalimumab", "infliximab", and "etanercept".
|
28233109 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subsequently, similar positive efficacy for inhibition of IL-17A was seen in patients with ankylosing spondylitis and psoriatic arthritis.
|
28270233 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The availability of newer biologics targeting IL-17/1L23 has shown some promising results in slowing radiographic progression in AS.
|
28361330 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Initial observations suggest that JAK-STAT kinase signaling cascade regulates activation and proliferation of the IL17 effector memory T cells and thus has a potential role in the pathogenesis of psoriasis, psoriatic arthritis and ankylosing spondylitis.
|
28394822 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
|
28516874 |
2018 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing spondylitis.
|
28633806 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis.
|
28868144 |
2017 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We first detected that rs6693831 and rs1884444 in IL-23R gene and rs2275913 in IL-17A gene have genetic association with AS.
|
29050281 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secukinumab, an anti-interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2).
|
29273067 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
|
29283375 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, several points are discussed and summarized including recent advances on the role of the IL-17/IL-23 immune pathway in the pathogenesis of AS, HLA-B27, and ERAP 1 and 2 mediated pathogenesis, AS-related microbiota compositions, and new potential therapies for AS.
|
29409751 |
2018 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
(B27-HC)<sub>2</sub> binds to KIR3DL2 of NK and Th17 cells and activates both cells, resulting in the activation of the IL-23/IL-17 axis to launch the inflammatory reaction in AS patients.
|
29463951 |
2017 |